Apyx Medical Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Apyx Medical Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $8.30M | Mar 18, 2016 |
| FY2015 | Sep 30, 2015 | $7.82M | Mar 18, 2016 |
| FY2015 | Jun 30, 2015 | $7.27M | Mar 18, 2016 |
| FY2015 | Mar 31, 2015 | $6.13M | Mar 18, 2016 |
| FY2015 | Dec 31, 2014 | $7.47M | Mar 18, 2016 |
| FY2015 | Sep 30, 2014 | $6.79M | Mar 18, 2016 |
| FY2015 | Jun 30, 2014 | $6.95M | Mar 18, 2016 |
| FY2015 | Mar 31, 2014 | $6.48M | Mar 18, 2016 |
| FY2014 | Dec 31, 2013 | $6.13M | Feb 27, 2015 |
| FY2014 | Sep 30, 2013 | $5.79M | Feb 27, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.84M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $48.10M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $52.35M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $44.51M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $48.52M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $27.71M | Mar 17, 2022 |
| FY2019 | Dec 31, 2019 | $8.38M | Mar 31, 2020 |
| FY2019 | Sep 30, 2019 | $7.58M | Mar 31, 2020 |
| FY2019 | Jun 30, 2019 | $6.65M | Mar 31, 2020 |
| FY2019 | Mar 31, 2019 | $5.63M | Mar 31, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $5.93M | Mar 14, 2019 |
| FY2018 | Sep 30, 2018 | $3.67M | Mar 14, 2019 |
| FY2018 | Jun 30, 2018 | $3.69M | Mar 14, 2019 |
| FY2018 | Mar 31, 2018 | $3.40M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $3.66M | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $2.65M | Mar 14, 2019 |
| FY2018 | Jun 30, 2017 | $2.31M | Mar 14, 2019 |
| FY2018 | Mar 31, 2017 | $1.61M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $9.49M | Mar 13, 2018 |
| FY2017 | Sep 30, 2016 | $10.06M | Mar 13, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.04M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $29.36M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $33.76M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $29.13M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $33.60M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $17.50M | Mar 17, 2022 |
| FY2019 | Dec 31, 2019 | $5.56M | Mar 31, 2020 |
| FY2019 | Sep 30, 2019 | $5.29M | Mar 31, 2020 |
| FY2019 | Jun 30, 2019 | $4.67M | Mar 31, 2020 |
| FY2019 | Mar 31, 2019 | $3.56M | Mar 31, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.21M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($23.46M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($18.71M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($23.18M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($15.17M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($11.90M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($19.71M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $62.72M | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | $68.47M | Mar 31, 2020 |
| FY2019 | Dec 31, 2017 | ($5.06M) | Mar 31, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.45M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($18.85M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($17.26M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($23.56M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($14.45M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($20.08M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($20.87M) | Mar 31, 2021 |
| FY2019 | Mar 31, 2019 | ($5.73M) | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | ($14.28M) | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | ($2.79M) | Mar 31, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $5.08M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $5.44M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $4.54M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.32M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.92M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $3.73M | Mar 31, 2021 |
| FY2019 | Sep 30, 2019 | $1.02M | Mar 31, 2020 |
| FY2019 | Jun 30, 2019 | $1.62M | Mar 31, 2020 |
| FY2019 | Mar 31, 2019 | $730.0K | Mar 31, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.80M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $18.86M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $22.20M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $20.48M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $18.62M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $11.69M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $13.70M | Mar 31, 2021 |
| FY2019 | Sep 30, 2019 | $3.84M | Mar 31, 2020 |
| FY2019 | Jun 30, 2019 | $3.04M | Mar 31, 2020 |
| FY2019 | Mar 31, 2019 | $2.96M | Mar 31, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.00M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($18.05M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($5.25M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($20.28M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($10.45M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($16.07M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($18.48M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($20.88M) | Mar 31, 2020 |
| FY2019 | Dec 31, 2017 | ($3.70M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2016 | ($2.84M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $722.0K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $533.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.01M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $723.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $581.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.30M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $363.0K | Mar 31, 2020 |
| FY2019 | Dec 31, 2017 | $624.0K | Mar 31, 2020 |
| FY2018 | Dec 31, 2016 | $286.0K | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.84M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $64.84M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $79.24M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $51.78M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $68.72M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $74.11M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $84.75M | Mar 31, 2021 |
| FY2019 | Mar 31, 2019 | $91.86M | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | $95.93M | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | $113.17M | Mar 31, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.01M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $50.51M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $52.32M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $13.98M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.71M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $10.25M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $13.49M | Mar 31, 2021 |
| FY2019 | Mar 31, 2019 | $9.03M | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | $8.75M | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | $22.58M | Mar 31, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.54M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $14.21M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $26.70M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $37.58M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $53.70M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $63.72M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $71.26M | Mar 31, 2021 |
| FY2019 | Mar 31, 2019 | $82.83M | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | $87.18M | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | $90.60M | Mar 31, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $185.0K | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $185.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $185.0K | Mar 13, 2018 |
| FY2016 | Dec 31, 2015 | $185.0K | Mar 10, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($89.12M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($77.91M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($54.45M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($35.74M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($12.55M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $2.62M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $14.52M | Mar 31, 2021 |
| FY2019 | Sep 30, 2019 | $19.95M | Mar 31, 2020 |
| FY2019 | Jun 30, 2019 | $24.32M | Mar 31, 2020 |
| FY2019 | Mar 31, 2019 | $28.62M | Mar 31, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.74M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $31.74M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $43.65M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $10.19M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $30.87M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $41.92M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $58.81M | Mar 31, 2021 |
| FY2019 | Mar 31, 2019 | $32.42M | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | $16.60M | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | $40.66M | Mar 31, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.50M | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | $37.50M | Mar 13, 2025 |
| FY2017 | Dec 31, 2017 | $2.69M | Mar 13, 2018 |
| FY2016 | Dec 31, 2016 | $2.93M | Mar 10, 2017 |
| FY2015 | Dec 31, 2015 | $140.0K | Mar 18, 2016 |
| FY2014 | Dec 31, 2013 | $3.19M | Feb 27, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 31, 2020 |
| FY2018 | Dec 31, 2018 | (100) | Mar 14, 2019 |
| FY2019 | Sep 30, 2018 | 2 | Mar 31, 2020 |
| FY2018 | Jun 30, 2018 | 0 | Mar 14, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | 1 | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | 1 | Mar 31, 2020 |
| FY2019 | Dec 31, 2017 | 0 | Mar 31, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 14, 2019 |
| FY2015 | Dec 31, 2015 | 0 | Mar 18, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.79M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 37.79M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 34.64M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 34.60M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 34.41M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 34.29M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 34.17M | Mar 31, 2021 |
| FY2019 | Mar 31, 2019 | 33.89M | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | 33.70M | Mar 31, 2020 |
| FY2019 | Sep 30, 2018 | 33.62M | Mar 31, 2020 |